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Tay–Sachs diseaseAbstract Neurometabolic disorders are a group of inborn errors of metabolism where neurolog-
ical symptoms predominate especially convulsions which are usually resistant to antiepileptic drugs.
Other symptoms include poor feeding, vomiting, lethargy, seizures, and loss of consciousness.
Because of the nonspecific overlapping symptoms, confirming the diagnosis depends mainly on
the specific investigation that is done in highly specialized laboratories.
The clinical picture can be more complicated in the presence of two diseases in the same family
and more difficult if present in the same patient. This is not extremely rare in countries with high
prevalence of consanguineous marriage like Egypt. The situation is more complicated when we add
the lack of specific investigations, metabolic specialized labs and the deficiency of documentation.
In this case report, we present the challenges that we met in diagnosis and counseling of a family
with both Tay–Sachs and maple syrup urine disease depending mainly on history, clinical data and
a few diagnostic investigations.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inborn errors of metabolism (IEM) result from the lack of
activity of one or more specific enzymes or defects in the trans-
portation of proteins that result in the accumulation of sub-
stances usually present in small amounts, the deficiency of
critical intermediary products, the deficiency of specific final
products or furthermore the noxious excess of products of
alternative metabolic pathways [1].
Maple syrup urine disease (MSUD) is an autosomal recessive
disease associated with defects in the branched chain a ketoacid
dehydrogenase complex (BCKD) resulting in a buildup ofbranched chain amino acids which are neurotoxic that cause
swelling of the white matter causing lethargy, reduced muscle
tone, and convulsions [2]. MSUD is divided into four major cat-
egories of classic, intermediate, intermittent, and thiamine
responsive [3].
The GM2-gangliosidoses is considered a heterogeneous
group of disorders resulting from a failure in lysosomal
hydrolysis of GM2-ganglioside; due to a primary deficiency of
the b-hexosaminidase A (b-hex A) enzyme or its cofactor
(the GM2activator protein) [4]. The classic infantile form
(Tay–Sachs (TSD) or Sandoff disease) is characterized by the
onset at 4–8 months and progressive neurological deteriora-
tion with macular cherry-red spots, blindness, intractable sei-
zures and paralysis. Late onset Tay–Sachs disease is
characterized by progressive spasticity and rigidity, convulsion
and dementia that have its onset in childhood or later [5].
It is classified into juvenile onset form in which individuals
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15 years and an adult form that manifests later with cerebellar,
anterior horn cell involvement and sometimes with neuropsy-
chiatric problems [6].
Although both diseases are categorized as IEM and both
have a progressive course, patients with TSD usually acquire
normal milestones of development in the first 6 months of life
while patients with MSUD have an acute onset of neurological
symptoms in the first few days of life [5,11]. Unless proper
investigations are requested, the differentiation between the
two diseases is extremely difficult.
Here we report an Egyptian patient who had both MSUD
and TSD and the challenges we faced in diagnosis and counsel-
ing of this family.
2. Case report
A first cousin parents were referred to the Genetics Clinic
because of repeated infant deaths. They had three children
(two girls and one boy) with convulsions that start a few hours
after birth and failure to thrive that ended by their death after
a few months. They had also a fourth child (girl) who was nor-
mal till the age of 6 month then developed hypotonia, progres-
sive loss of previously acquired milestones of development and
convulsions that also ended by her death at the age of
14 months. There was also a maternal cousin who had mental
retardation and convulsions and died at the age of 4 years,
Fig. 1. No diagnostic investigation was done before their death.
The parents were counseled that they may probably have two
recessive diseases as the onset and the course of the disease in
their children is different, one of them could be TSD (beingA A
?
C
Figure 1 Family pedigree. (A) poor suckling, failure to thrive and co
6 month then developed hypotonia, progressive loss of previously a
retardation died at the age of 4 years.the most common disease with this presentation) with the possi-
bility of testing them for the carrier status. Carrier testing for the
mother revealed reduced leucocyte and plasma activity of Hex-
osaminidase A enzyme indicating a carrier status for TSD,
Table 1. Genetic counseling was done with the recommendation
of testing the husband and prenatal diagnosis for TSD.We also
stressed upon the fact that TSD does not explain the early death
of the three children with neonatal convulsions and so testing
further pregnancy outcome by extendedmetabolic screen is also
mandatory. We lost contact with the family and then they pre-
sented to the genetics clinic after one year with a three week
old newborn girl suffering from poor suckling and respiratory
distress. The patient was delivered at full term by cesarean sec-
tion and the parents confirmed that they did prenatal diagnosis
of TSD disease at nine weeks of pregnancy in another lab using
enzyme assay and revealed normal result. The result of the pre-
natal diagnosis was not available. Extended metabolic screen
was done and revealed elevation of branched-chain amino acids
leucine, isoleucine and valine diagnostic of MSUD. She started
treatment immediately in the formof protein restriction and spe-
cial MSUD milk formula and had almost normal physical and
mental development till the age of 10 months when she devel-
oped generalized tonic–clonic convulsions for which she was
prescribed anticonvulsants (Sominaletta and Tiratam) with no
proper control. It was also noticed that she had a gradual dete-
rioration of vision and loss of previously acquired milestones of
development. She also developed hypertonia in both upper and
lower limbs with exaggerated deep tendon reflexes. Fundus
examination was done and revealed bilateral pale optic disc.
Diagnosis of Tay–Sachs disease was confirmed by enzymatic
assay. The parents were counseled again explaining theA B
nvulsions, died at the age of 1–3 months. (B) Normal till the age of
cquired milestones of development and convulsions. (C) Mental
Table 1 Carrier screening of Tay–Sachs disease in the mother.
Sample Mother Control
Activity in leucocytes
(nmoles/h/mg protein)
Total b-
hexosaminidase
1114 1488
b-Hexosaminidase
A
257 874
b-Hexosaminidase
A/total
0.23 0.59
b-Hexosaminidase
A substrate specific
45 149
Activity in plasma
(nmoles/h/ml protein)
Total b-
hexosaminidase
928 780
b-Hexosaminidase
A substrate specific
53 76
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taken for diagnosis of their child. The patient was kept on
the MSUD diet and the levels of branched chain amino acids
were always controlled but her neurological status progressively
deteriorated till her death at the age of 2 years.
3. Discussion
We report a 3 year old child with two rare recessive neu-
rometabolic diseases with overlapping symptoms and signs
that may confuse the treating physician if the family history
is not carefully investigated. The occurrence of two recessive
genetic diseases in the same family has been reported before
and sometimes it can suggest a different diagnosis [7]. This
may be attributed to the high prevalence of consanguineous
marriages in Egyptian population [8].
Consanguineous mating is genetically important as closely
related individuals have a higher chance of carrying the same
alleles than unrelated individuals; hence the offspring of con-
sanguineous mating are more frequently homozygous for var-
ious alleles than those from other unions [9].
The absence of medical records and lack of investigations in
the deceased children is another challenge that we had to over-
come and we had to search for other clues in history and clin-
ical picture to elucidate what diseases this family might have
had that led to the tragic death of three children.
MSUD is an autosomal recessive inborn error of metabo-
lism leading to accumulation of the branched-chain amino
acids (leucine, isoleucine, and valine) which are toxic to the
central nervous system and can produce different grades of
neuropathy, or even death, if the disease is not treated [10].
The worldwide incidence of MSUD is approximately 1 in
185, 000 live births [10] while the prevalence in our clinic
(the largest clinic for IEM in Egypt) is 13.4% of all patients
with IEM [personal communication]. Onset of the disease is
usually after a few days of birth [11]. This is in contrast to
GM2 in which the child is normal for a longer period ranging
from 4 to 8 months and then progressively have neurological
deterioration with macular cherry-red spots, blindness, intract-
able seizures and paralysis [5]. This difference of onset was the
most important clue in family history that indicated the pres-
ence of two different diseases in the same family.
Hexosaminidase A enzymatic activity is the primary
method of population screening and carrier detection ofTSD disease because of its greater sensitivity compared to tar-
geted mutation analysis [12].
Being a country with limited medical and financial
resources, searching of the other disease in the family using
molecular testing was not applicable or cost effective and so
genetic counseling explaining the importance of selective new-
born screening in the next pregnancy was done.
Selective screening is carried out in neonates and children
who develop symptoms or have family history indicative of
an IEM [13]. There are a few Arab countries in the Middle
East and North Africa region that have started a newborn
screening (NBS) program, while others have either a limited
hospital-based selective NBS program or have just completed
pilot studies [14–16]. Recently, Egypt has recently started a
newborn screening for only PKU and hypothyroidism.
Neonatal screening and sophisticated enteral and par-
enteral treatment protocols have significantly improved neuro-
logical outcome in patients with classic MSUD but risks of
acute brain injury or death are always present and the long-
term neuropsychiatric prognosis is guarded [10,17].
Our patient had gradual deterioration of vision and started
to loose previously acquired milestones of development in spite
of good metabolic control of MSUD evidenced by repeatedly
optimal plasma levels of branched chain amino acids. This
should direct the treating physician to search for another dis-
ease, like TSD in this family.
TSD occurs at high frequency in Ashkenazi Jewish indi-
viduals due to a shared genetic background, with an inci-
dence of 1 in 2500 to 3900 live births compared to 1 in
320,000 in the general population [18]. Following the devel-
opment of prenatal diagnosis for TSD in the early 1970’s
[19], most couples who had had an affected child chose to
monitor subsequent pregnancies and bring to term only preg-
nancies of unaffected fetuses as the parents of our patient
did. However, Chorionic villus sampling (CVS) has been per-
formed at 9 menstrual weeks for the prenatal enzymatic diag-
nosis of TSD and revealed normal enzymatic assay. This
could be explained by maternal cell contamination [20] which
should always be excluded by microsatellite analysis in all
samples of prenatal testing and that was not done to the cur-
rent patient.
4. To conclude
The occurrence of two recessive diseases in the same patient is
not rare in the Egyptian population due to the high prevalence
of consanguineous marriage. This may complicate the clinical
picture, the diagnosis and management. Reaching an accurate
diagnosis is of utmost importance for proper genetic counsel-
ing and family planning.Conflict of interest
The authors declared no potential conflicts of interests with
respect to the authorship and/or publication of this article.
Acknowledgement
The authors thank dr. Shimaa Gad and dr. Nada Hammad for
helping in management of this patient.
250 H.S. Abd-Elkhalek et al.References
[1] Waber L. Inborn errors of metabolism. Pediatr Ann
1990;19:105–17.
[2] Watts R. Inborn errors of metabolism. In: Weatherall J, Dingham
L, Warrell D, editors. Oxford textbook of medicine. Oxford:
Oxford University Press; 1987. p. 1.
[3] Chuang D, Shih V. Disorders of branched chain amino acid and
keto acid metabolism. In: Scriver C, Beaudet A, Sly W, Valle D,
editors. The metabolic basis of inherited disease. New York:
McGraw-Hill; 1995. p. 1250–65.
[4] Gravel R, Kaback M, Proia P, Sandhoff K, Suzuki K, Suzuki K.
The GM2 gangliosidoses. In: Beaudet A, Scriver CR, Sly WS,
Valle D, editors. The metabolic and molecular bases of inherited
diseases. New York: McGraw-Hill; 2001. p. 3827–76.
[5] Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok
F, et al. The natural history of juvenile or subacute GM2
gangliosidosis: 21 new cases and literature review of 134
previously reported. Pediatrics 2006;118:e1550–62.
[6] Neudorfer O, Kolodny EH. Late-onset Tay–Sachs disease. Isr
Med Assoc J 2004;6:107–11.
[7] Ebermann I, Elsayed SM, Abdel-Ghaffar TY, Nu¨rnberg G,
Nu¨rnberg P, Elsobky E, et al. Double homozygosity for mutations
of AGL and SCN9A mimicking neurohepatopathy syndrome.
Neurology 2008;70:2343–4.
[8] Shawky RM, El-Awady YM, Elsayed SM, Hamadan GE.
Consanguineous mating among Egyptian population. Egypt J
Med Hum Genet 2011;12:157–63.
[9] Mueller RF, Young ID. Polygenic and multifactorial inheritance.
In: Mueller RF, Young ID, editors. Emery’s elements of medical
genetics. Edinburgh: Churchill Livingstone; 1995.
[10] Strauss KA, Wardley B, Robinson D, Hendrickson C, Rider NL,
Puffenberger EG, et al. Classical maple syrup urine disease andbrain development: principles of management and formula design.
Mol Genet Metab 2010;99:333–45.
[11] Nyhan WL, Barshop BA, Ozand PT. Atlas of metabolic diseases,
2nd ed., 2005 chapter 24. NY: Oxford University Press; 2005. p.
160–1.
[12] Schneider A, Nakagawa S, Keep R, Dorsainville D, Charrow J,
Aleck K, et al. Population-based Tay–Sachs screening among
Ashkenazi Jewish young adults in the 21st century: hex-
osaminidase A enzyme assay is essential for accurate testing.
Am J Med Genet A 2009;149A(11):2444–7.
[13] Hoffmann GF, Trefz FK, Rating D, Bremer HJ. Selective
screening for amino and organic acid inborn errors. Wien Klin
Wochenschr 1992;104(21):651–7.
[14] Al-Gazali L, Hamamy H, Al-Arrayad S. Genetic disorders in the
Arab world. BMJ 2006;333(7573):831–4.
[15] Elsobky E, Elsayed S. Extended metabolic screen in sick neonates
and children. Egypt J Med Hum Genet 2004;5(2):1–7.
[16] Shawky R, Abd-Elkhalek H, Elakhdar SE. Selective screening in
neonates suspected to have inborn errors of metabolism. Egypt J
Med Hum Genet 2015;16(2):165–71.
[17] Muelly ER, Moore GJ, Bunce SC, Mack J, Bigler DC, Morton
DH, et al. Biochemical correlates of neuropsychiatric illness in
maple syrup urine disease. J Clin Invest 2013;123:1809–20.
[18] Stenson PD, Ball EV, Howells K, Phillips AD, Mort M, Cooper
DN. The human gene mutation database: providing a compre-
hensive central mutation database for molecular diagnostics and
personalised genomics. Hum Genomics 2009;4(2):69–72.
[19] Schneck L, Valenti C, Amsterdam D, Friedland M, Adachi M,
Volk BW. Prenatal diagnosis of Tay–Sachs disease. Lancet
1970;1:582–3.
[20] Fowler B, Giles L, Cooper A, Sardharwalla IB. Chorionic villus
sampling: diagnostic uses and limitations of enzyme assays. J
Inherit Metab Dis 1989;12(Suppl. 1):105–17.
